Current version snapshot

FDA-approved↗↗Rare disease↗

Current · version 3: Setmelanotide↗

Related names recorded in this version: Imcivree↗

An MC4 receptor agonist approved by FDA as Imcivree for acquired hypothalamic obesity, Bardet-Biedl syndrome and certain genetic deficiencies, not for general obesity.↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked the Imcivree label, and added the Drugs@FDA approval record. 12

What this version reported

A randomized, placebo-controlled trial in 142 people with acquired hypothalamic obesity and smaller open-label trials in genetic forms of obesity are described in the label. The label states that it is not indicated for general obesity.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗
  • U.S. Food and Drug Administration↗

Reader guide in this version

Key takeaway

Setmelanotide is a lab-made peptide that activates the MC4 receptor, part of a brain pathway that regulates hunger and energy use, and is the active ingredient in Imcivree from Rhythm.1,2 It is FDA-approved only for specific rare causes of obesity: acquired hypothalamic obesity from age 4, and Bardet-Biedl syndrome or genetically confirmed POMC, PCSK1 or LEPR deficiency from age 2. The label states that it is not indicated for general obesity.1 Its evidence comes from small trials, including a randomized, placebo-controlled trial of 142 people with acquired hypothalamic obesity.1

At a glance

What it is
An MC4 receptor agonist. The label states that it has about 20-fold less activity at the MC3 and MC1 receptors.1
FDA status
FDA-approved. Drugs@FDA lists Imcivree with an original approval date of November 25, 2020, and the label limits it to specific rare causes of obesity. The cited label has no boxed warning.1,2
Human evidence
A randomized, placebo-controlled trial in 142 people with acquired hypothalamic obesity, and smaller open-label trials in genetic forms of obesity, described in the label.1
Evidence strength
Smaller controlled human trials

What is setmelanotide?

Setmelanotide is a lab-made peptide that the label describes as an MC4 receptor agonist.1

In the United States it is the active ingredient of Imcivree, from Rhythm, according to Drugs@FDA.2

How does setmelanotide work?

The label states that MC4 receptors in the brain are involved in regulating hunger, fullness and energy use, and that, based on nonclinical evidence, setmelanotide may restore activity in this pathway in conditions where it is not activated enough.1

The label also states that setmelanotide acts weakly on the MC1 receptor on pigment cells, which can darken the skin.1

What do human studies show?

In a randomized, double-blind, placebo-controlled trial in 142 people aged 4 and older with acquired hypothalamic obesity, body-mass index fell by an average of 18.40 percentage points more with setmelanotide than with placebo after 52 weeks, according to the label.1

In 44 people with Bardet-Biedl syndrome, the average change in body-mass index after 52 weeks of treatment was −7.9%, and 38.7% had a reduction of at least 10%, according to the label. That result comes from the open-label part of the trial.1

The label also describes one-year open-label trials in 21 people with POMC, PCSK1 or LEPR deficiency and a trial in 12 children aged 2 to under 6. These trials had no parallel placebo group for their main results.1

What the evidence base contains

  • Controlled human trial Trial 1 (NCT05774756): a randomized, double-blind, placebo-controlled trial of 56 to 60 weeks in 142 people aged 4 and older with acquired hypothalamic obesity.1
  • Controlled human trial Trial 2 (NCT03746522): 44 people with Bardet-Biedl syndrome, with a 14-week randomized, placebo-controlled period followed by 52 weeks of open-label treatment.1
  • Small, short, or incompletely reported human study Two one-year open-label trials in 21 people with POMC, PCSK1 or LEPR deficiency (NCT02896192 and NCT03287960), and a 52-week open-label trial in 12 children aged 2 to under 6.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is setmelanotide FDA-approved?

Yes. Drugs@FDA lists Imcivree, application NDA213793, with an original approval date of November 25, 2020.2

The Imcivree label cited here (DailyMed SPL version 14, published April 2, 2026) states that it is indicated to reduce excess body weight and maintain the reduction long term in people aged 4 and older with acquired hypothalamic obesity, and in people aged 2 and older with Bardet-Biedl syndrome or POMC, PCSK1 or LEPR deficiency confirmed by genetic testing.1

The label states that it is not indicated for obesity linked to benign gene variants or for other types of obesity, including general (polygenic) obesity, where it would not be expected to work.1

The label has no boxed warning. It states that setmelanotide is contraindicated in people with prior serious allergic reactions to it, and its warnings cover sexual-arousal effects, depression and suicidal thoughts, allergic reactions, skin darkening and new or darker moles, and, in acquired hypothalamic obesity, acute adrenal insufficiency and sodium imbalance in people with central diabetes insipidus.1

Timeline

  1. FDA approves Imcivree, according to Drugs@FDA.2
  2. DailyMed publishes the Imcivree label version cited on this page.1

What is still unknown?

Its effects in general obesity, for which the label says it is not indicated and would not be expected to work.1

How durable the results are in the genetic obesity trials, which were small and mostly open-label.1

Sources for this version

  1. 1
    IMCIVREE (setmelanotide) solution · SPL version 14 · published 2026-04-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA213793 · original submission status AP · 2020-11-25 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026